Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

Peptide antigens are combined with an adjuvant in order to increase immunogenicity in vivo. The immunogenicity and safety of a RSV vaccine formulated in a novel oil-based platform, DepoVax™ (DPX), was compared to an alum formulation. A peptide B cell epitope derived from RSV small hydrophobic ectodo...

Full description

Bibliographic Details
Main Authors: Lisa D. MacDonald, Alecia MacKay, Valarmathy Kaliaperumal, Genevieve Weir, Andrea Penwell, Rajkannan Rajagopalan, Joanne M. Langley, Scott Halperin, Marc Mansour, Marianne M. Stanford
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
adjuvant
vaccine
rsv
alum
hypersensitivity
depot
Online Access:http://dx.doi.org/10.1080/21645515.2017.1375637

Internet

http://dx.doi.org/10.1080/21645515.2017.1375637

Similar Items